Drug Action
Enfuvirtide inhibits the fusion of HIV to the host cell.
PDF page 700
Loading InternPractice…
Drug reference
Enfuvirtide inhibits the fusion of HIV to the host cell.
PDF page 700
HIV infection in combination with other antiretroviral drugs for resistant infection or for patients intolerant to other antiretroviral regimens ▶BY SUBCUTANEOUS INJECTION ▶Adult: 90 mg twice daily
PDF page 700
▶Common or very common Anxiety. appetite decreased. asthenia. concentration impaired. conjunctivitis. diabetes mellitus. gastrooesophageal reflux disease. haematuria. hypertriglyceridaemia. increased risk of infection. influenza like illness. irritability. lymphadenopathy. myalgia. nasal congestion. nephrolithiasis. nightmare. numbness. pancreatitis. peripheral neuropathy. skin papilloma. skin reactions. tremor. vertigo. weight decreased ▶Frequency not known Diarrhoea. hypersensitivity. immune reconstitution inflammatory syndrome. nausea. osteonecrosis SIDE-EFFECTS, FURTHER INFORMATION Hypersensitivity Hypersensitivity reactions including rash, fever, nausea, vomiting, chills, rigors, low blood pressure, respiratory distress, glomerulonephritis, and raised liver enzymes reported; discontinue immediately if any signs or symptoms of systemic hypersensitivity develop and do not rechallenge. Osteonecrosis Osteonecrosis has been reported in patients with advanced HIV disease or following long-term exposure to combination antiretroviral therapy.
PDF page 700
Manufacturer advises use only if potential benefit outweighs risk.
PDF page 700
Manufacturer advises caution (no information available); increased risk of hepatic side effects in patients with chronic hepatitis B or C.
PDF page 700
For subcutaneous injection, reconstitute with 1.1 mL Water for Injections and allow to stand (for up to 45 minutes) to dissolve; do not shake or invert vial.
PDF page 700
There can be variation in the licensing of different medicines containing the same drug. Powder and solvent for solution for injection ELECTROLYTES: May contain Sodium ▶Fuzeon (Roche Products Ltd) Enfuvirtide 108 mg Fuzeon 108mg powder and solvent for solution for injection vials | 60 vial P £1,081.57 ANTIVIRALS › HIV-INTEGRASE INHIBITORS
PDF page 700
Hypersensitivity reactions Patients or carers should be told how to recognise signs of hypersensitivity, and advised to discontinue treatment and seek immediate medical attention if symptoms develop.
PDF page 700
90 mg twice daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 700